Table 4.
Comparison of SVR12 outcomes in direct-acting antiviral regimen studies with or without comparative groups, according to population group and task-shifting status
| Non-specialist care, % (95% CI) | Specialist care, % (95% CI) | p value | ||
|---|---|---|---|---|
| People who inject drugs | ||||
| Comparative | 93% (86–98) | 95% (92–97) | 0·460 | |
| Wade et al (2018), RCT | PCPs or nurses 100% (76–100) | 100% (74–100) | .. | |
| McClure et al (2017), PCS | Nurses 88% (78–95); GPs 93% (82–99) | 93% (90–95) | .. | |
| Non-comparative | 96% (94–98) | 92% (86–96) | 0·145 | |
| Number of studies | 22 | 8 | .. | |
| General population | ||||
| Comparative | 95% (92–98) | 94% (91–96) | 0·466 | |
| Cooper et al (2017), RCS | Nurses 95% (74–100) | 95% (91–97) | .. | |
| Kattakuzhy et al (2017), NRS | PCPs 95% (90–98); nurses 95% (90–98) | 92% (89–95) | .. | |
| Non-comparative | 93% (87–97) | 94% (91–97) | 0·737 | |
| Number of studies | 5 | 9 | .. | |
| People living with HIV | ||||
| Comparative | 94% (88–98) | 100% (93–100) | 0·065 | |
| Doyle et al (2018), NRS | Nurses 94% (88–98) | 100% (93–100) | .. | |
| Non-comparative | 99% (97–100) | NA | NA | |
| Number of studies | 3 | 0 | .. | |
A full list of studies is provided in the appendix (pp 2–25). p values for comparative studies were from pairwise meta-analyses of dichotomous outcomes. p values for non-comparative studies were from two-sample z-tests comparing the results of meta-analyses for proportions using double arcsin transformations. SVR12=sustained virological response at 12 weeks after completion of treatment. RCT=randomised controlled trial. PCP=primary care physician. PCS=prospective comparative study. GP=general practitioner. RCS=retrospective comparative study. NRS=non-randomised study. NA=not applicable (tests could not be performed due to a paucity of data).